Williams-Sonoma Stock Split: Mark Your Calendars for June 27 Williams-Sonoma (NYSE: WSM ) stock is a hot topic on Thursday after the home products retailer announced a stock split coming next month. According to the company, this stock split will result in it splitting each share of WSM stock into two shares. This will happen through a stock dividend that will see investors in Williams-Sonoma get one extra share for each one that they own. Williams-Sonoma says that shareholders have to be on record as of June 27 to be eligible for the stock split. That will see them get the extra stock through the dividend when markets close on July 8. Following that, shares of WSM stock will start trading on a split-adjusted basis on July 9. The company also notes that the stock split won’t affect voting and other rights of shareholders. Williams-Sonoma is enacting this stock split to attract new investors. That includes making it easier for its employees to invest in WSM shares. Williams-Sonoma Stock Split Dividend Alongside the stock split dividend, the company also announced a quarterly cash dividend payable on August 23.
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers' Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
Why Is Cara Therapeutics (CARA) Stock Down 27% Today? Cara Therapeutics (NASDAQ: CARA ) stock is falling hard on Thursday after the development-stage biopharmaceutical company announced new data from a clinical trial. This data comes from the company's Part A KOURAGE-1 study.
Canaccord Genuity downgrades Cara Therapeutics stock after trial failure https://www.investing.com/news/company-news/canaccord-genuity-downgrades-cara-therapeutics-stock-after-trial-failure-93CH-3482537
Cara Therapeutics discontinues study on a neurological condition as drug fails Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo.
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica – Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP).
Cara, an artist-run, anti-AI social platform, grew from 40K to 650K users in the past week, as some Instagram artists leave over plans to train AI on user data (Amanda Silberling/TechCrunch) Amanda Silberling / TechCrunch : Cara, an artist-run, anti-AI social platform, grew from 40K to 650K users in the past week, as some Instagram artists leave over plans to train AI on user data — ‘Building a product is a bit like making art,’ said founder Jingna Zhang — Artists have finally had enough with Meta''s predatory AI policies …
CARA Stock Earnings: Cara Therapeutics Misses EPS, Beats Revenue for Q1 2024 Cara Therapeutics (NASDAQ: CARA ) just reported results for the first quarter of 2024. Cara Therapeutics reported earnings per share of -56 cents. This was below the analyst estimate for EPS of -40 cents. The company reported revenue of $2.14 million. This was 26.33% better than the analyst estimate for revenue of $1.69 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates Cara Therapeutics (CARA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.49 per share a year ago.